Moreover, Fc–IL-4 synergized with current type I immunity-centric adoptive T cell transfer and immune checkpoint blockade therapies to induce durable remission across several syngeneic and xenograft tumor models, which highlighted the potential of orchestrating type I and type II immunity to advance next-generation cancer immunotherapy [2]. This evidence concerns the gene IL4 and neoplasm.